

**Rhesus Theta Defensin 1 Promotes Long Term Survival in Systemic Candidiasis by Host
Directed Mechanisms**

Virginia Basso¹, Dat Q. Tran^{1,2}, Justin B. Schaal¹, Patti Tran¹, Yoshihiro Eriguchi¹, Diana Ngole¹,
Anthony E. Cabebe¹, A young Park³, Paul M. Beringer³, André J. Ouellette^{1,4}, and Michael E.
Selsted^{*1,2,4}

¹Department of Pathology and Laboratory Medicine, Keck School of Medicine, University of
Southern California, Los Angeles, California, United States of America


²Oryn Therapeutics, Vacaville, California, United States of America

³Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, Los
Angeles, United States of America

⁴Norris Comprehensive Cancer Center of the University of Southern California, Los Angeles
California, United States of America

*Address correspondence to Michael E. Selsted, selsted@med.usc.edu

Suppl. Fig. 1



Suppl. Figure 1. Goodness-of-fit plots of the final PK model. (a) Observed RTD-1 concentrations versus model predicted concentrations following i.v. injection ($R^2 = 0.9774$; slope \pm SE = 1.111-61.04) using linear regression, and (b) conditional standardized residuals versus model prediction.

Suppl. Table 1. Log-rank analysis for Fig. 3.

	RTD-1 i.p.	RTD-1 s.c.	RTD-1 i.v.	Caspo	Fluco
Saline	3.3×10^{-7}	1.5×10^{-5}	6.9×10^{-4}	4.3×10^{-7}	4.3×10^{-7}
RTD-1 i.p.	-	ns	ns	0.019	ns
RTD-1 s.c.	-	-	ns	3.1×10^{-3}	ns
RTD-1 i.v.	-	-	-	5.7×10^{-3}	ns
Caspo	-	-	-	-	0.014

a. RTD-1 efficacy is independent of route of peptide administration.

b. RTD-1 efficacy *in vivo* is dose-dependent.

	20 mg/kg	10 mg/kg	5 mg/kg	2.5 mg/kg	0.5 mg/kg	0.25 mg/kg
Saline	6.3×10^{-5}	0.013	3.3×10^{-7}	1.5×10^{-6}	1.5×10^{-4}	4.0×10^{-5}
20 mg/kg	-	6.3×10^{-5}	3.7×10^{-5}	6.3×10^{-5}	6.3×10^{-5}	6.3×10^{-5}
10 mg/kg	-	-	9.4×10^{-5}	1.2×10^{-3}	2.1×10^{-3}	0.024
5 mg/kg	-	-	-	ns	ns	ns
2.5 mg/kg	-	-	-	-	ns	ns
0.5 mg/kg	-	-	-	-	-	ns

c. Dependence of single dose RTD-1 efficacy on time of administration.

	RTD-1 T=0 h	RTD-1 T=1 h	RTD-1 T=3 h	RTD-1 T=6 h
Saline	3.3×10^{-7}	2.7×10^{-3}	1.5×10^{-4}	1.7×10^{-3}
RTD-1 T=0 h	-	4.3×10^{-3}	2.5×10^{-4}	7.0×10^{-3}
RTD-1 T=1 h	-	-	ns	ns
RTD-1 T=3 h	-	-	-	ns

d. Daily RTD-1 treatment beginning 24 h after infection promotes survival.

	RTD-1	Caspo	Fluco
Saline	3.4×10^{-6}	3.4×10^{-6}	3.4×10^{-6}
RTD-1	-	ns	ns
Caspo	-	-	4.7×10^{-3}

Supplementary Table 2. Parameter estimates for the final pharmacokinetic model for RTD-1

Model parameter	Final model	
	Mean	SE (CV%)
CLt (mL/h)	14.17	7.179
Vc (mL)	14.58	13.19
CLd (mL/h)	3.248	18.22
Vp (mL)	24.88	19.02
K10 (h ⁻¹)	0.9719	8.379
λ1 (h ⁻¹)	1.221	8.829
λ2 (h ⁻¹)	0.1039	13.20
T1/2-λ1 (h)	0.5676	8.829
T1/2-λ2 (h)	6.672	13.20
F	0.6344	

CLt, total clearance; Vc, central volume of distribution; Ka, absorption rate constant; CLd, distributional clearance; Vp, peripheral volume; K10, elimination rate constant from the central compartment; λ1, distribution rate constant, λ2, terminal rate constant; T1/2-λ1, distribution half-life; T1/2-λ2, terminal half-life; F, bioavailability.